A composition for assisting in lowering uric acid

Abstract

The present invention discloses a composition for assisting in reducing uric acid, the composition includes the following ingredients: black sesame, polygonatum powder, purple sweet potato extract and honey, and the mass fraction of ingredients in the composition is 50-80 parts of black sesame, 15-30 parts of polygonatum powder, 5-10 parts of honey, and 10-25 parts of purple sweet potato extract. The preparation method of the present invention is simple and low in cost. The composition prepared by scientifically combining 4 kinds of specific ingredients has been proved to have a good effect on reducing uric acid by daily consumption of hyperuricemia, and can reduce uric acid for patients with mild hyperuricemia. For patients with moderate and severe hyperuricemia, daily consumption of the composition can coordinate uric acid reduction and reduce medication. The composition of the present invention can be applied to the preparation of common food and health food.

Description

Technical Field

[0001] The present invention belongs to the technical field of uric acid lowering compositions, and specifically relates to a composition for assisting in lowering uric acid. Background Art

[0002] Uric acid in the human body mainly comes from the metabolism of purine substances. When an adult has a normal purine diet and the fasting blood uric acid level exceeds the standard (≥420 μmol / L) twice on different days, it is called hyperuricemia. The crystal deposition of urate in the joints of the human body leads to gout. According to statistics, there are about 177 million people with hyperuricemia and about 14.66 million people with gout in China. Hyperuricemia and gout have become the fourth largest health hazard after the "three highs". Hyperuricemia is a biochemical marker of gout, which means that the urate in the extracellular fluid is supersaturated. About 5%-12% of hyperuricemia patients will develop gout, which will also cause damage to renal function. Therefore, controlling hyperuricemia has important clinical significance.

[0003] At present, the clinical treatment of hyperuricemia mainly includes drug therapy and dietary intervention. Among them, drug therapy has become a common means of clinical treatment due to its short treatment cycle and quick effect, but drugs for the clinical treatment of hyperuricemia such as Febuxostat, Allopurinol, Benzbromarone, etc. have great side effects. For example, Febuxostat can easily cause abnormal liver function, Allopurinol can cause adverse skin reactions, Benzbromarone can cause digestive system discomfort, etc., and patients will become dependent on long-term use, and uric acid is prone to rebound after stopping the drug, and it also affects other functions of the patient's body. Dietary intervention is used as an auxiliary treatment to enhance the effect of drug therapy, but because conventional dietary intervention is slow to take effect and patient compliance is poor, restricting diet to reduce uric acid is very limited. Summary of the invention

[0004] In order to solve the shortcomings and deficiencies in the above-mentioned prior art, the present invention is based on the principle of "medicine and food have the same origin" and provides a low-cost, safe, and effective uric acid-lowering composition and application through daily consumption.

[0005] The technical solution of the present invention is as follows:

[0006] A composition for assisting in lowering uric acid is prepared from the following raw materials: black sesame, polygonatum sibiricum powder, purple sweet potato extract and honey.

[0007] Furthermore, the mass proportions of the raw materials in the composition are 50-80 parts of black sesame, 15-30 parts of polygonatum powder, 5-10 parts of honey, and 10-25 parts of purple sweet potato extract.

[0008] Furthermore, the weight proportions of the raw materials in the composition are: 70 parts of black sesame, 15 parts of polygonatum powder, 5-10 parts of honey, and 15-20 parts of purple sweet potato extract.

[0009] Furthermore, the mass parts of the raw materials in the composition are: 70 parts of black sesame, 15 parts of polygonatum powder, 5 parts of honey, and 15 parts of purple sweet potato extract.

[0010] Furthermore, the mass parts of the raw materials in the composition are: 80 parts of black sesame, 20 parts of polygonatum powder, 5 parts of honey, and 20 parts of purple sweet potato extract.

[0011] Furthermore, the composition is in the form of pills or granules.

[0012] The preparation method of the composition comprises the following steps:

[0013] Step 1: Prepare purple sweet potato extract: take a whole fresh purple sweet potato, wash it with clean water 2-3 times, dry it in the sun naturally, and then grind it into a powder with a fineness of 200-300 mesh using a low-temperature ultra-fine wall-breaking grinder, and immediately bag it and vacuum it and store it at a temperature of 4°C;

[0014] Step 2: preparing black sesame seeds: taking black sesame seeds with full grains, removing impurities, washing, drying, frying mature black sesame seeds at a temperature of 150-250° C., grinding until the black sesame seeds produce oil, and grinding into powder with a fineness of 25-35 mesh;

[0015] Step 3: Bake the purple sweet potato extract described in step 1 at low temperature for 20 minutes, take it out and cool it to room temperature for later use;

[0016] Step 4: Boil the honey over medium heat for 20 minutes, cool to below 50°C and set aside;

[0017] Step 5: Mix the black sesame powder prepared in step 2, the purple sweet potato extract prepared in step 3, and the polygonatum powder and stir evenly, then pour into the honey prepared in step 4 and stir until a uniform paste is obtained;

[0018] Step 6: Make into pills or granules, bake at 55℃±5℃ for 20 minutes, take out, and package after cooling.

[0019] Furthermore, the temperature of the low-temperature baking is 50°C±5°C.

[0020] The composition of the present invention is used in preparing a health product for assisting in reducing uric acid.

[0021] The polygonatum powder in the formula of the present invention is commercially available ginger-shaped polygonatum powder (i.e., polyanthus powder), which is processed from ginger-shaped polygonatum. There is no special requirement for the grade of the raw material polygonatum, and the polygonatum with thick stem flesh, irregular block or nodular block, yellow-brown to dark brown surface, rough, and ginger-like appearance is mainly selected to be processed into powder. Polygonatum powder is sweet and flat in nature, and has the effects of anti-oxidation, anti-fatigue and anti-aging. People usually eat a moderate amount of polygonatum powder to improve their body immunity and accelerate the metabolism of the human body. Polygonatum powder can regulate the spleen and stomach and relieve lung yin deficiency, and can prevent deficiency of essence and blood and premature graying of hair. In addition, polygonatum powder has obvious preventive and therapeutic effects on human blood pressure and arteriosclerosis.

[0022] The composition provided by the present invention has main ingredients that are all food materials, which are safe for long-term use without side effects, and the preparation method is simple and low in cost. The present invention prepares the composition by scientifically combining four specific raw materials, and experiments have shown that daily use of the composition has a good promoting effect on lowering uric acid. For patients with mild hyperuricemia, uric acid can be reduced; for patients with moderate to severe hyperuricemia, daily use of the composition can synergistically reduce uric acid, reduce the amount of drugs taken or enhance the therapeutic effect of drugs. DETAILED DESCRIPTION

[0023] To better illustrate the purpose, technical solutions and advantages of the present invention, the present invention is further described by the following examples. Obviously, the following examples are only a part of the embodiments of the present invention, rather than all the embodiments. It should be understood that the embodiments of the present invention are only used to illustrate the technical effects of the present invention, rather than to limit the scope of protection of the present invention.

[0024] If no specific techniques or conditions are specified in the following examples, the techniques or conditions described in the literature in the art or the product instructions are used. All reagents or instruments without manufacturer specified are conventional products that can be purchased commercially. Example 1

[0025] The present embodiment provides a composition for assisting in lowering uric acid, comprising the following raw material components in parts by weight: 70 parts of black sesame, 15 parts of polygonatum powder, 5 parts of honey, and 15 parts of purple sweet potato extract.

[0026] Wherein, the preparation method of purple sweet potato extract is as follows:

[0027] Take a whole plant of fresh purple sweet potato, wash it with clean water 2-3 times, air-dry it naturally into a dry plant, and then use a low-temperature ultra-fine wall-breaking grinder to grind it into a powder with a fineness of 300 mesh. Immediately pack it into a bag, evacuate it, and store it at a temperature of 4°C.

[0028] The preparation method of black sesame is as follows:

[0029] Take black sesame seeds with full grains, remove impurities, wash, dry, and fry them at 200°C until they are mature, and grind them until the black sesame seeds produce oil and the fineness is 20 mesh powder.

[0030] The preparation method of honey is as follows:

[0031] Put the honey into a stainless steel bowl and boil over medium heat for 20 minutes. Cool to 45℃ and set aside.

[0032] Bake the purple sweet potato extract in an oven at 50°C for 20 minutes, take it out and cool it to room temperature for later use;

[0033] The prepared black sesame powder, purple sweet potato extract and polygonatum powder are mixed and stirred evenly, poured into honey and stirred until a paste with a uniform texture is formed, and then made into pills or granules, baked at a temperature of 55° C. for 20 minutes, taken out, and packaged after cooling. Example 2

[0034] The present embodiment provides a composition for assisting in lowering uric acid, comprising the following raw material components in parts by weight: 80 parts of black sesame, 20 parts of polygonatum sibiricum powder, 5 parts of honey, and 20 parts of purple sweet potato extract.

[0035] The prepared black sesame powder, purple sweet potato extract and polygonatum powder are mixed and stirred evenly, poured into honey and stirred until a paste with a uniform texture is formed, and then made into pills or granules, baked at a temperature of 50° C. for 20 minutes, taken out, and packaged after cooling.

[0036] In this embodiment, purple sweet potato extract is prepared: fresh purple sweet potato leaves are taken, washed with clean water 2-3 times, naturally air-dried into dry plants, and then ground into powder with a low-temperature ultra-fine wall-breaking grinder with a fineness of 250 mesh, and immediately bagged and vacuumed and stored at a temperature of 4°C for later use; the preparation method of black sesame and honey is the same as the preparation method in Example 1. Example 3

[0037] The present embodiment provides a composition for assisting in lowering uric acid, comprising the following raw material components in parts by weight: 50 parts of black sesame, 30 parts of polygonatum powder, 10 parts of honey, and 25 parts of purple sweet potato extract.

[0038] In this embodiment, acacia honey is used as honey, and the preparation method of purple sweet potato extract, black sesame and honey is the same as the preparation method in Example 2. Example 4

[0039] The present embodiment provides a composition for assisting in lowering uric acid, comprising the following raw material components in parts by weight: 60 parts of black sesame, 30 parts of polygonatum powder, 6 parts of honey, and 10 parts of purple sweet potato extract.

[0040] In this embodiment, a purple sweet potato extract is prepared. The temperature of low-temperature baking in the step of preparing the purple sweet potato extract is 45° C. The preparation method of black sesame and honey is the same as the preparation method in Example 3.

[0041] The technical effect of the present invention is further confirmed by the following verification test.

[0042] Test Example 1: Effect of reducing uric acid in hyperuricemia mice

[0043] Construction of hyperuricemia mouse model: The mice used were SPF grade 1-month-old male KM mice. After 1 week of adaptive feeding, the mice were fasted for 12-14 hours and had free access to water. The fasting body weight was measured the next day, and blood was collected from the inner canthus after anesthesia to detect the basic data of blood uric acid. The mice were randomly divided into a blank group and 4 model groups (A, B, C, and D) according to the fasting body weight, with 9 mice in each group. Hypoxanthine and potassium oxonate were prepared into a suspension using 0.5% sodium carboxymethyl cellulose solution. The model group was first gavaged with hypoxanthine 500 mg / (kg·d), and then gavaged with potassium oxonate 1000 mg / (kg·d) 2 hours later, with a total gavage volume of 0.3 ml / (10 g·d); the blank group was gavaged with an equal volume of distilled water for 7 days. During the modeling period, mice in each group had free access to water and were fed with the same mass of feed. After 7 days of modeling, blood was taken for SUA test, indicating that the modeling was successful.

[0044] The mice with successful modeling were further divided into four groups: A, B, C, and D. They were treated with physiological saline, allopurinol, a low dose (1200 mg / kg) suspension of the composition of Example 2, and a high dose (2400 mg / kg) suspension of the composition of Example 2 by gavage for 3 consecutive days, and then serum was collected to detect the blood uric acid level of each mouse. The results are shown in Table 1:

[0045]

[0046] As can be seen from Table 1, after drug-induced modeling, the blood uric acid levels of mice in the model group increased significantly, and then the hyperuric acid model mice were treated with allopurinol, low-dose Example 2 composition, and high-dose Example 2 composition, respectively, and the blood uric acid levels of mice in each treatment group decreased significantly. Among them, compared with the modeling group A without drug treatment, the blood uric acid levels of most mice in the group treated with the composition (groups C and D) were significantly reduced (a few changes were not obvious and belonged to individual differences, which were within the normal experimental error range). The test results prove that daily consumption has a good effect on lowering uric acid.

[0047] Test Example 2: Effect of reducing uric acid in patients with hyperuricemia

[0048] This experiment was conducted as a project collaboration with the hospital and was carried out after obtaining ethical approval.

[0049] Recruiting volunteers. Volunteers participating in this project meet the following conditions: those who are over 18 years old, volunteer to be tested and guarantee cooperation, and must also meet the following standards: under normal diet, fasting blood uric acid levels are higher than the upper limit of normal values ​​for two different days, among which men are >420 μmol / L and women are >357 μmol / L. Exclusion criteria are: (1) under 18 years old; (2) pregnant or lactating women, those with allergic constitution and those who are allergic to this sample; (3) those with serious diseases such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system and endocrine diseases, and mental patients; (4) alcoholics; (5) those who have taken drugs related to the test function within 3 months, affecting the judgment of the results; (6) those who do not meet the inclusion criteria, do not take the test samples as required, cannot determine the efficacy or have incomplete data that affects the judgment of efficacy or safety. Finally, as of December 2022, there are more than 200 people in this project. Excluding those who do not meet the inclusion conditions and those who are lost to follow-up, there are currently 150 volunteers in the group, which meets the requirements of the ethical approval. Of these, 121 have completed the test.

[0050] The volunteers were informed of the purpose of the experiment and precautions, and the changes in the blood uric acid levels of the volunteers were detected before and after taking the composition prepared in Example 3 for 2 consecutive weeks to analyze the uric acid-lowering effect of the composition of the present invention. Method: The composition prepared in Example 3 was taken 3 times a day, before breakfast, lunch, and dinner, 2 pills each time.

[0051] After taking the composition for 2 weeks, the uric acid reduction effect of the volunteers compared with that before taking the composition is shown in Table 2:

[0052]

[0053] Since the uric acid value data before and after the product did not follow a normal distribution, the Wilcoxon signed rank test of paired samples was used. The results showed that Z = -5.370, P < 0.01, and the uric acid value after taking the product was significantly lower than the uric acid value before taking it. The median uric acid values ​​before and after taking the product were 492 and 449, respectively, with a decrease rate of about 10%.

[0054] Among all the subjects, 86 people had reduced blood uric acid within 2 weeks after taking the composition, accounting for 71.1% of the population; 60 people had significant effective results, and the significant effective rate was about 50% (2-week uric acid reduction rate ≥ 7%, uric acid reduction rate = (uric acid value after taking the composition - uric acid value before taking the composition) / uric acid value before taking the composition).

[0055] In addition to the uric acid lowering effect, some volunteers also felt smooth bowel movements and reduced night sweats after taking the composition prepared in Example 3. This shows that the composition of the present invention has certain nutritional and health functions in addition to lowering uric acid.

[0056] The results of Examples 1-4 and Test Examples 1-2 show that, whether in animal experiments or human food trials, taking the composition of the present invention can achieve a good uric acid-lowering effect in a relatively short period of time, and the effect is better when taken for a long time.

[0057] The above is a detailed description of the embodiments of the present invention, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

Claims

1. A composition for assisting in lowering uric acid, characterized in that: The composition is prepared from the following raw materials in parts by weight: 50-80 parts of black sesame, 15-30 parts of polygonatum powder, 5-10 parts of honey, and 10-25 parts of purple sweet potato extract; The preparation method of the purple sweet potato extract is as follows: take a whole fresh purple sweet potato, wash it with clean water 2-3 times, dry it in the sun naturally, and then grind it into powder with a low-temperature ultra-fine wall-breaking grinder to a fineness of 200-300 mesh, immediately bag it, evacuate it and store it at a temperature of 4°C; The preparation method of black sesame comprises the following steps: taking black sesame with full grains, removing impurities, washing, sun-drying, frying the black sesame at a temperature of 150-250° C. until mature black sesame is ripe, grinding the black sesame until oil is produced, and grinding the black sesame into powder with a fineness of 25-35 meshes.

2. The composition according to claim 1, characterized in that The composition is prepared from the following raw materials in parts by mass: 70 parts of black sesame, 15 parts of polygonatum sibiricum powder, 5-10 parts of honey, and 15-20 parts of purple sweet potato extract.

3. The composition according to claim 2, characterized in that The composition is prepared from the following raw materials in parts by mass: 70 parts of black sesame, 15 parts of polygonatum sibiricum powder, 5 parts of honey, and 15 parts of purple sweet potato extract.

4. The composition according to claim 1, characterized in that The composition is prepared from the following raw materials in parts by mass: 80 parts of black sesame, 20 parts of polygonatum sibiricum powder, 5 parts of honey, and 20 parts of purple sweet potato extract.

5. The composition according to claim 1, characterized in that The composition is in the form of pills or granules.

6. A method for preparing the composition according to any one of claims 1 to 5, characterized in that: The preparation method comprises the following steps: Step 1: bake the purple sweet potato extract at low temperature for 20 minutes, take it out and cool it to room temperature for later use; Step 2: Boil the honey over medium heat for 20 minutes, cool to below 50°C and set aside; Step 3: Mix the prepared black sesame, purple sweet potato extract and polygonatum powder and stir evenly, pour into honey and stir until a uniform paste is formed; Step 4: Make into pills or granules, bake at 55℃±5℃ for 20 minutes, take out, and package after cooling.

7. The method for preparing the composition according to claim 6, characterized in that: The temperature of the low-temperature baking is 50°C±5°C.

8. Use of the composition according to any one of claims 1 to 4 in the preparation of a health product for assisting in lowering uric acid.

Images